Ozempic (semaglutide) is a once-weekly injectable medication that belongs to a drug class called glucagon-like peptide-1 (GLP-1) receptor agonists
Funding This work was in part supported by Fondi di Ateneo from the Universit della Calabria (to CI, MS, MG, and LP) and in part by PON (Programma Operativo Nazionale) Project No
Did the authors limit the types of persons with Parkinsons disease who were allowed to enroll in the trial
The Adjustment Period Most digestive side effects occur during the first few weeks of treatment or immediately following a dose increase
"The analyses from STEP UP presented at ECO are really promising, further highlighting the potential of the higher dose of Wegovy to achieve substantial weight loss," said Emil Kongshj Larsen, Novo Nordisk's head of international operations
Clinical practice guidelines for the management of overweight and obesity published internationally: A scoping review